Botanix Pharmaceuticals Announces Successful Atopic Dermatitis Study Results

Medical dermatology company Botanix Pharmaceuticals Limited announced the successful results of its randomised, double-blind, vehicle (placebo) controlled Phase 1b atopic dermatitis (AD) patient study, designed to evaluate the safety, tolerability and pharmacology of BTX 1204.

The randomised, double-blind, vehicle-controlled Phase 1b study was conducted at five dermatology sites in Australia and enrolled 37 patients with mild to moderate atopic dermatitis. Eligible patients were randomised to receive either BTX 1204 or the vehicle (placebo – contains no active drug) applied twice daily for four weeks. 25 patients were randomly assigned to the BTX 1204 group and 12 patients were randomly assigned to the vehicle group. While primarily a safety study, the study also assessed for early signs of efficacy through improvements in the signs and symptoms of AD following treatment. 32 patients successfully completed the Phase 1b study.

Top line data indicates BTX 1204 was well-tolerated as there were no significant adverse effects, or reports of skin irritation during the study. The effects of BTX 1204 on the Signs of AD were assessed by comparing the proportion of patients achieving treatment success with BTX 1204 after 4 weeks of treatment, to the proportion of patients achieving treatment success treated with the vehicle. Treatment success was defined as a greater than, or equal to a 4 point improvement in the Signs of AD. After 4 weeks of treatment, 35% of patients receiving BTX 1204 achieved treatment success, compared to only 18% of patients who received the vehicle.

Botanix Executive Director Matt Callahan said “these results show that BTX 1204 was twice as effective as the vehicle in providing a clinical meaningful outcome to patients with AD. We are extremely encouraged by these positive results. BTX 1204’s efficacy profile is in line with existing topical products whose treatment success rates are typically between 25-35%. This combined with the excellent safety profile demonstrated to date underlines the potential for BTX 1204 to be a very safe and exciting new treatment for the millions of patients who suffer from this disease.”

Even though the study was not statistically powered to show differences in efficacy, significant improvements from baseline in each individual sign of AD including erythema (inflammation), exudation (ooze from the lesion) and lichenification (thickening of the skin in response to itching) were observed after 4 weeks in patients treated with BTX 1204, compared with patients receiving the vehicle. An important outcome of the study was the improvement observed in those Signs of AD, that are associated with the chronic form of the disease, specifically a reduction in exudation and lichenification. These key signs are more severe in chronic AD and are directly related to an increase in itch (pruritis) of the lesions. As there is currently no effective treatment for chronic sufferers of itch (whether AD patients or as a symptom of other skin diseases), BTX 1204 represents a potential new treatment for these patients.

Dr Kurt Gebauer, a key opinion leader in dermatology and Clinical Associate Professor of Dermatology commented, “physicians and patients require new treatment options for mild to moderate atopic dermatitis with improved side effect profiles particularly for the many children suffering from this condition. The safety of BTX 1204 and the known safe therapeutic use of synthetic cannabidiol in children for other diseases, points to BTX 1204 potentially being a significant new therapy for atopic dermatitis.”

Based on these results, Botanix plans to review the corporate opportunities for the further development of BTX 1204, either pursuant to a partnering or licensing arrangement with other dermatology companies, or through conducting a Phase 2 study for BTX 1204.

Mr Callahan added, “In addition to confirming the significant potential of BTX 1204 for atopic dermatitis, these results again provide further evidence of the anti-inflammatory effects of synthetic cannabidiol. Inflammation is a consistent theme across the other common skin diseases that Botanix is targeting. These results continue to validate and support the broader potential of the Botanix product portfolio.”


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s